Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI may help tailor cancer care for seniors, study puts it to the test

NCT ID NCT07805642

Knowledge-focused Sponsor: Latin American Cooperative Oncology Group Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 04, 2026 · Last updated Sep 04, 2026

Summary

This study tests whether a machine learning model called PROTEGER can help doctors choose the right cancer treatment for adults aged 65 and older with solid tumors. Researchers will train the model on past patient data, then check its accuracy in a new group of patients across Chile, Peru, and Brazil. The model uses information from a comprehensive geriatric assessment to recommend standard treatment, a reduced dose, or supportive care only. The goal is to see if the tool can predict which patients will benefit from intensive treatment and which might face serious side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Machine learning-based decision-support model (PROTEGER) that recommends cancer treatment intensity based on geriatric assessment data
What this could lead to
If it works, this could give oncology teams a reliable tool to tailor cancer treatment for older adults, reducing harmful side effects while keeping treatment effective.
What could go wrong
The model is still being developed and validated, so it may not perform accurately across different patient groups. Also, the study is observational, so it cannot prove the tool improves outcomes directly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 412 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of older adults (aged 65 years and older) diagnosed with solid tumor cancers who receive care in public and private health institutions in South America (Chile, Brazil, and Peru). The retrospective cohort includes anonymized historical data from patients evaluated by the Oncogeriatric Tele-Committee of the Chilean Ministry of Health. The prospective cohort comprises consecutive patients seen in routine oncological care who undergo a Comprehensive Geriatric Assessment (CGA) and are managed by local oncogeriatric teams.

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 65 years or older. * Diagnosis of solid tumor cancer. * Must have been evaluated and followed up by a local oncology team. * Signed Informed Consent Form (ICF) applied in accordance with the local ethics committee. * Must have undergone a Comprehensive Geriatric Assessment (CGA). Exclusion Criteria: \- Patients who are unable or unwilling to consent to providing information will be excluded.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Solid tumor cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Solid tumor cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • BR192 HCOR - Hospital do Coração

    São Paulo, São Paulo, 04004-060, Brazil

  • HIAE - Hospital Israelita Albert Einstein

    São Paulo, São Paulo, 05653-000, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.